Century Therapeutics, Inc. (IPSC) stock

IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30

$1.65+0.02 (+1.23%)

Close on Nov 13, 2026Market cap $298.77MP/E –Yield –

Century Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Century Therapeutics's price to sales ratio was 1.8× on Apr 30, 2026, against 7.1× a year earlier. Over the last 3 years it ranged from 0.4× to 130.8×, with a median of 31.8×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Apr 30, 2026	1.8×	+1.1
2025	Dec 31, 2025	0.8×	−31.0
2024	Dec 31, 2024	31.8×	−47.6
2023	Dec 29, 2023	79.4×	–

Where these numbers come from

Parsed from the XBRL in Century Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing